Generics - Biotechnology, Markets & Marketing

Filter

Popular Filters

1 to 25 of 39 results

Biocad enters deal for exporting rituximab biosimilar to Turkey

22-08-2013

Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

New Florida law takes a major step in promoting access to biologic medicines

06-06-2013

Legislation amending the US state of Florida's existing prescription drug substitution law has the potential…

BiotechnologyGenericsLegalMarkets & MarketingNorth AmericaRegulation

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData

10-05-2013

The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Global biosimilar drug revenues will reach $2,445 million in 2013, says Visiongain

08-05-2013

The world market for biosimilar drugs will be worth $2,445 million in 2013, growing by more than 20%…

BiotechnologyCellTrionGenericsGlobalHospiraMarkets & MarketingSandoz

Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar

17-04-2013

USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018

10-04-2013

US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent…

BiotechnologyBoehringer IngelheimGenentechGenericsMarkets & MarketingNorth AmericaNovartisPfizerRespiratory and PulmonarySpirivaXolair

Both biosimilar and reference biologics companies must consider product-specific and regional strategies

09-04-2013

With sales forecasted to exceed $16.8 billion by 2021, manufacturers competing in the biosimilars market…

BiotechnologyGenericsMarkets & MarketingPatentsProductionResearch

Indian Pharma growth outpaces rivals, but must embrace innovation

12-03-2013

Ranking among the top five globally by production volume, the Indian pharmaceutical market at present…

Asia-PacificBiotechnologyGenericsMarkets & MarketingPharmaceuticalProductionResearch

Mylan extends deal with Biocon to biosimilar insulins, as Actavis pulls out of JV

14-02-2013

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBioconBiotechnologyDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

US pharma organizations work together to foster supply chain security and integrity

31-01-2013

The 100th meeting of the USA-based National Conference of Pharmaceutical Organizations (NCPO) - consisting…

BiotechnologyGenericsHealthcareMarkets & MarketingNorth AmericaPharmaceutical

Indian pharmaceuticals market led by Ranbaxy in terms of revenue

31-01-2013

The Indian pharmaceutical market is the world's third-largest in terms of volume and stands 14th in terms…

Asia-PacificBioconBiotechnologyGenericsMarkets & MarketingPanacea BiotecPharmaceuticalRanbaxy LaboratoriesSerum Institute of India

Australia's pharma sector a net importer but also one of its largest high-tech exporters

13-01-2013

The pharmaceutical product manufacturing industry in Australia is dominated by major global pharmaceutical…

Asia-PacificBiotechnologyGenericsMarkets & MarketingPharmaceuticalProduction

Sales of antiretroviral agents for HIV will decline slightly over next decade

18-12-2012

Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

Biosimilars threaten to burst Humira's blockbuster bubble

29-11-2012

US health care major Abbott Laboratories' (NYSE: ABT) Humira (adalimumab) has a strong reputation as…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGenericsHumiraMarkets & Marketing

Big Pharma embraces biologics

21-11-2012

Fast-evolving biopharmaceuticals will challenge synthetic market dominance in the global market for active…

BiotechnologyGenericsGlobalMarkets & Marketing

Brazilian generic industry review

07-11-2012

The Brazilian pharmaceutical market is growing rapidly into one of the largest pharma markets in the…

BiotechnologyGenericsMarkets & MarketingSouth America

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021

04-11-2012

Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021

28-10-2012

While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

US nephrologists expect rapid adoption of USA's first biosimilars - epoetin alfa

09-10-2012

More than 60% of surveyed nephrologists in the USA expect to begin prescribing biosimilar epoetin alfa…

BiotechnologyDiabetesGenericsMarkets & MarketingNephrology and Hepatology

"Sandoz will be the leading biosimilars company in 2012," says Visiongain

04-10-2012

Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global…

BiotechnologyDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingNovartisSandoz

World awaits "Biosimilars Boom," says GBI Research

01-10-2012

With an introduction to the USA set for 2014, and the realization of massive potential in the emerging…

BiotechnologyGenericsGlobalMarkets & Marketing

Uptake of biosimilars will see Remicade and Humira sales decline in 2017

26-09-2012

The TNF-alpha inhibitors infliximab (Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade) and adalimumab…

BiotechnologyGastro-intestinalsGenericsGlobalHumiraMarkets & MarketingRemicade

1 to 25 of 39 results

Back to top